Abstracts tagged "Juvenile idiopathic arthritis"

Abstract Number: 131 • 2023 Pediatric Rheumatology Symposium
Improving Methotrexate Documentation in Electronic Health Records – a Quality Improvement Initiative
Jayne MacMahon¹, Jeanine McColl², Alaa Al-Shehab¹, Deborah Levy³, Ronald laxer¹ and Shirley Tse¹, ¹University of Toronto, The Hospital for Sick Children, Toronto, ON, Canada, ²University of Alberta, Edmonton, AB, Canada, ³The Hospital for Sick Children, Toronto, ON, Canada
Background/Purpose: Prescribing methotrexate,is common practice in rheumatology. Appropriate medication counselling and documentation is important. In our province, as per thephysician regulatory body the College of…
Abstract Number: 094 • 2023 Pediatric Rheumatology Symposium
Provider Assessment of the Temporomandibular Joint in Juvenile Idiopathic Arthritis
Anna Costello¹, Marinka Twilt² and Melissa Lerman¹, ¹Children's Hospital of Philadelphia, Philadelphia, PA, ²Alberta Children's Hospital, Calgary, AB, Canada
Background/Purpose: TM joint arthritis is an underrecognized complication of JIA that can cause long-term problems including decreased mandibular growth, altered facial morphology, and orofacial pain.…
Abstract Number: 132 • 2023 Pediatric Rheumatology Symposium
Quality Improvement Lessons in a New Practice
Farah Shaya, Sharon Bout-Tabaku and Buthaina Al-Adba, Sidra Medicine, Ar-Rayyan, Qatar
Background/Purpose: Children with Juvenile Idiopathic Arthritis (JIA) have better disease outcomes with current medications available, yet there is variability in these outcomes. Quality improvement (QI)…
Abstract Number: L12 • ACR Convergence 2022
First Line Treatment Using Recombinant IL-1Receptor Antagonist in New Onset Systemic Juvenile Idiopathic Arthritis Is an Effective Treatment Strategy, Irrespective of HLA DRB1 Background
Remco Erkens¹, Rashmi Sinha², Alex Pickering³, Grant Schulert⁴, Alexei Grom⁴, Lars van der Veken¹, Hanneke van Deutekom¹, Jorg Calis¹, Jorg van Loosdregt⁵ and Sebastiaan Vastert¹, ¹University Medical Center Utrecht, Utrecht, Netherlands, ²Systemic JIA Foundation, Cincinnati, OH, ³Systemic JIA Foundation, San Francisso, CA, ⁴Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁵University Medical Center Utrecht, Wilhelmina Children's Hospital, Zeist, Netherlands
Background/Purpose: Systemic Juvenile Idiopathic Arthritis (sJIA) is a severe subtype of JIA. Recently, interstitial lung disease (SJIA-LD) has been reported as a severe complication of…
Abstract Number: 0858 • ACR Convergence 2022
Predicting the Occurrence of Drug-Free Inactive Disease Two Years After Diagnosis of Non-Systemic Juvenile Idiopathic Arthritis
Melissa Mannion¹, Chen Chen², Olha Halyabar³, Susan Paetkau⁴, Tingting Qiu⁵ and Bin Huang⁶, ¹University of Alabama at Birmingham, Birmingham, AL, ²Cincinnati Children's Hospital Medical Center, Taipei, Taiwan, ³Children's Hospital/Boston Medical Center, Boston, MA, ⁴The Hospital for Sick Children, Toronto, ON, Canada, ⁵Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁶Cincinnati Children's Hospital Medical Center, Cinciannati, OH
Background/Purpose: The goal of treatment for juvenile idiopathic arthritis (JIA) is inactive disease (ID), but the optimal treatment for each patient to maximize ID and…
Abstract Number: 1097 • ACR Convergence 2022
Intrinsic STAT1 Deficiency Underlies Proinflammatory Imprint of Naive CD4+ T Cells in Spondyloarthritis
Bilade CHERQAOUI¹, Frederic Cremazy¹, Marc Lauraine¹, Ghazal Shammas², Roula Said-Nahal³, Hendrick Mambu Mambueni⁴, Felicie Costantino², Marine Fourmont², Simon Glatigny², Luiza Maria Araujo² and Maxime Breban², ¹INSERM U1173, UFR Simone Veil, Versailles-Saint Quentin / Paris-Saclay University, Montigny-le-Bretonneux, France, ²1INSERM U1173, UFR Simone Veil, Versailles-Saint Quentin / Paris-Saclay University, Montigny-le-Bretonneux, France, ³Rheumatology Division - Ambroise Pare Hospital, APHP, Boulogne-Billancourt, France, ⁴Genomic Platform of Faculty of Health Simone Veil - UVSQ university, Montigny-le-Bretonneux, France
Background/Purpose: Spondyloarthritis (SpA) development is associated with type 3 immune response activation. In HLA-B27/human β2-microglobulin transgenic rat model (B27-rat), this might at least be related…
Abstract Number: PP22 • ACR Convergence 2022
Patients Raising Awareness for Patients – A Collaborative Partnership Between Take a Pain Check Foundation and Canadian Arthritis Patient Alliance
Natasha Trehan¹ and Laurie Proulx², ¹Take a Pain Check Foundation, Markham, ON, Canada, ²Canadian Arthritis Patient Alliance, Ottawa, ON, Canada
Background/Purpose: Juvenile Idiopathic Arthritis is a chronic disease that affects a child's school life and relationships, creating social isolation for youth and young adults. Take…
Abstract Number: 0004 • ACR Convergence 2022
mTORC1 Drives the Spectrum of Pathology in Systemic JIA and Macrophage Activation Syndrome
zhengping huang¹, xiaomeng You², Liang Chen³, Yan Du³, Kailey Brodeur³, Qiang Wang³, David Sykes⁴, Margaret Chang⁵, Julia Charles², Peter Nigrovic⁵ and Pui Lee⁵, ¹Guangdong Second Provincial Hospital, Guangzhou, China, ²Brigham and Women's Hospital, Boston, MA, ³Boston Children's Hospital, Boston, MA, ⁴Massachusetts General Hospital, Boston, MA, ⁵Division of Immunology, Boston Children's Hospital, Boston, MA
Background/Purpose: Systemic juvenile idiopathic arthritis (sJIA) is a severe inflammatory syndrome characterized by fever, skin rash and arthritis. A subset of patients with sJIA develop…
Abstract Number: 0859 • ACR Convergence 2022
Systemic Juvenile Idiopathic Arthritis Associated Lung Disease in Europe
Claudia Bracaglia¹, Francesca Minoia², Christoph Kessel³, Sebastiaan Vastert⁴, Manuela Pardeo¹, Alessia Arduini¹, Ozge Basaran⁵, Nural kiper⁶, Mikhail Kostik⁷, Mia Glerup⁸, Sarka Fingerhutova⁹, Roberta Caorsi¹⁰, AnnaCarin Horne¹¹, Giovanni Filocamo¹², Helmut Wittkowski³, Marija Jelusic¹³, Jordi Anton¹⁴, Samira Khaldi-Plassart¹⁵, Alexandre Belot¹⁶, Gerd Horneff¹⁷, Seraina Palmer Sarott¹⁸, Elvira cannizzaro Schneider¹⁸, Pavla Dolezalova⁹, Angelo Ravelli¹⁹, Seza Ozen²⁰ and Fabrizio De Benedetti¹, ¹Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesu', Rome, Italy, ²Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy, ³Department of Pediatric Rheumatology & Immunology, WWU Medical Center (UKM), Münster, Germany, ⁴Pediatric Rheumatology & Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ⁵Department of Pediatrics, Division of Pediatric Rheumatology, Hacettepe University, Ankara, Turkey, ⁶Department of Pediatrics, Division of Pediatric Pulmonology, Hacettepe University, Ankara, Turkey, ⁷Saint-Petersburg State Pediatric Medical University, Saint Petersburg, Russia, ⁸Department of Pediatrics, Aarhus University Hospital, Aarhus, Denmark, ⁹Centre for Paediatric Rheumatology and Autoinflammatory Diseases , Department of Paediatrics and Inherited Metabolic Disorders, 1st Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic, ¹⁰Department of pediatrics and Rheumatology, IRRCS Istituto G. Gaslini, Genova, Italy, ¹¹Department of pediatric rheumathology Karolinska University Hospital and Department of pediatrics, Karolinska Institute, Stockholm, Sweden, ¹²UOC Pediatria a Media Intensità di Cure, Clinica de Marchi, Milano, Italy, ¹³Department of Pediatrics, University of Zagreb School of Medicine, University Hospital Centre Zagreb, Zagreb, Croatia, ¹⁴Pediatric Rheumatology, Hospital Sant Joan de Déu, Universitat de Barcelona, Barcelona, Spain, ¹⁵Pediatric Nephrology, Rheumatology, Dermatology Unit, Hôpital Femme Mère Enfant, Hospices Civils de Lyon, Lyon, France, ¹⁶Hospices Civils de Lyon, Collonges au mont d'or, France, ¹⁷Pediatrics, Asklepios Klinik Sankt Augustin GmbH, Sankt Augustin, Germany, ¹⁸Paediatric Rheumatology University Children’s Hospital Zurich, Zürich, Switzerland, ¹⁹Department of Neurosciences, Rehabilitation, Ophthalmology, Genetic and Maternal Infantile Sciences (DINOGMI) University of Genoa, Italy,Scientific Direction, IRCCS Istituto Giannina Gaslini, Genova, Italy, ²⁰Hacettepe University Faculty of Medicine, Ankara, Turkey
Background/Purpose: Chronic parenchymal lung disease (LD) is a new emerging severe life-threatening complication of sJIA. The number of sJIA patients with LD is apparently increasing…
Abstract Number: 1103 • ACR Convergence 2022
Needs Assessment of Musculoskeletal Ultrasound Training in North American Pediatric Rheumatology Fellowship Programs
Megan Perron¹, Sonja Ziniel², Megan Curran³, Jessica Bloom⁴, Patricia Vega-Fernandez⁵, Heather Benham⁶, Karina Torralba⁷, Deirdre De Ranieri⁸ and Clara Lin⁹, ¹Children's Hospital Colorado, Division of Rheumatology, Aurora, CO, ²University of Colorado School of Medicine, Department of Pediatrics, Aurora, CO, ³University of Colorado, Aurora, CO, ⁴University of Colorado, Denver, CO, ⁵Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁶Scottish RIte Hospital, North Richland Hills, TX, ⁷Loma Linda University Faculty Medical Group, Redlands, CA, ⁸Lurie Children's Hospital, Chicago, IL, ⁹Children's Hospital Colorado, Aurora, CO
Background/Purpose: Musculoskeletal Ultrasound (MSUS) has become widely used in rheumatology practice for diagnosis of arthritis and procedural guidance. A 2017 survey of adult rheumatology fellowship…
Abstract Number: PP24 • ACR Convergence 2022
Planting Seeds of Self-Advocacy: Increasing Healthcare Engagement in Children and Adolescents Through Arthritis Camp
Kaye Anderson¹, Kristine Carandang² and Courtney Wells³, ¹Young Patients' Autoimmune Research & Empowerment Alliance, River Falls, WI, ²Young Patients' Autoimmune Research & Empowerment Alliance, San Diego, CA, ³University of Wisconsin-River Falls; Young Patients' Autoimmune Research and Empowerment Alliance, St. Paul, MN
Background/Purpose: I was diagnosed with Juvenile Idiopathic Arthritis at the age of ten. The constant battle between doctor appointments, pain, and medication side effects left…
Abstract Number: 0102 • ACR Convergence 2022
Impact of Racial Implicit Bias on Juvenile Idiopathic Arthritis Patients’ Treatment Recommendations
Alisha Akinsete¹, Illir Agalliu², Dawn Wahezi¹, Ellen Silvers², Onjona Hossain², Irene Blanco², Tamar Rubinstein³ and Cristina Gonzalez², ¹Children's Hospital at Montefiore, Bronx, NY, ²Albert Einstein College of Medicine, Bronx, NY, ³Albert Einstein College of Medicine, White Plains, NY
Background/Purpose: There are racial and ethnic disparities in juvenile idiopathic arthritis (JIA). Implicit bias can contribute to these health disparities through provider communication and medical…
Abstract Number: 0860 • ACR Convergence 2022
Characteristics of Transitioning JIA Patients: Who Is Arriving on the Adult Rheumatologists’ Doorsteps?
Teresa Semalulu¹, KAREN BEATTIE¹, Roberta Berard², Jaime Guzman³ and Michelle Batthish¹, ¹McMaster University, Hamilton, ON, Canada, ²London Health Sciences Centre, London, ON, Canada, ³University of British Columbia and BC Children's Hospital, Vancouver, BC, Canada
Background/Purpose: Patients with JIA are at an increased risk of loss to follow-up, morbidity and mortality as they transition from pediatric to adult care. Thus,…
Abstract Number: 1242 • ACR Convergence 2022
Validation of a Novel Ultrasound Scoring System for the Evaluation of Pediatric Knee Arthritis
Patricia Vega-Fernandez¹, Theresa Hennard¹, Kelly Rogers¹, Mekibib Altaye², Sherry Thornton², Alyssa Sproles², Amy Cassedy³, Arthur Meyers¹ and Tracy Ting¹, ¹Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Cincinnati Children's Hospital, Cincinnati, OH, ³Cincinnati Children's hospital medical center, Cleveland, OH
Background/Purpose: Juvenile Idiopathic Arthritis (JIA) is the most common chronic rheumatic disease in children. Currently, clinical evaluation of arthritis is subjective and provider dependent. Musculoskeletal…
Abstract Number: 0118 • ACR Convergence 2022
Sex-Based Variations in Emergency Department Utilization by Persons with Inflammatory Arthritis Conditions
Cheryl Barnabe¹, Patrick McLane², Nadia Luca¹, Katie Lin¹, Kelsey Chomistek¹, Meghan Elliott¹, Shanon McQuitty³, Eileen Davidson³, Clare Hildebrandt⁴, Steven Katz², Brian Holroyd² and Claire Barber¹, ¹University of Calgary, Calgary, AB, Canada, ²University of Alberta, Edmonton, AB, Canada, ³Arthritis Research Canada, Vancouver, BC, Canada, ⁴Patient and Family Advisors, Alberta Health Services, Calgary, AB, Canada
Background/Purpose: High quality ambulatory care provision should mitigate avoidable emergency department (ED) visits by persons with inflammatory arthritis (IA) conditions and address the unique realities…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].